Psoriasis trials in Italy
13 of 21 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 13 November 2026. Ask the study team whether a trial fits you.
- Phase 3Taking peopleContinuation Study of Zasocitinib in Adults With Psoriatic Arthritis
- Where
- Ancona, Florence, Milan, Padova, Pisa, Rome, Rozzano
- Age
- 18 years and over
- People
- 1,182 worldwide
- Run by
- Takeda
See details and how to joinNCT07286058 · EU 2025-522586-30-00 - Phase 4Taking peopleAn open-label, multi-center protocol for patients who have completed a previous Novartis sponsored Secukinumab study and are judged by the investigator to benefit from continued Secukinumab treatment
- Where
- Florence, Reggio Emilia
- People
- 339 worldwide
- Run by
- Novartis Pharma AG
See details and how to joinNCT04638647 · EU 2023-504417-67-00 - Phase 3Taking peopleA Long-term Extension (LTE) Study of Guselkumab in Pediatric Participants
- Where
- Bergamo, Bologna, Rome, San Giovanni Rotondo, Trieste
- Age
- 3 years to 64 years
- People
- 196 worldwide
- Run by
- Janssen Research & Development, LLC
See details and how to joinNCT06663332 · EU 2023-509560-16-00 - Phase 3Taking peopleLong-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK)
- Where
- Cagliari, Chieti Scalo, L'aquila, Modena, Naples, Rome, Rozzano
- Age
- 40 years and over
- People
- 3,040 worldwide
- Run by
- Bristol-Myers Squibb
See details and how to joinNCT07116967 · EU 2023-503766-24-00 - Phase 3Taking peopleA Study to Evaluate the Efficacy, Safety, and Drug Levels of Deucravacitinib (BMS-986165) in Adolescent Participants With Moderate to Severe Plaque Psoriasis
- Where
- Bologna, Rome
- Age
- 12 years to 17 years
- People
- 366 worldwide
- Run by
- Bristol-Myers Squibb
See details and how to joinNCT06979453 · EU 2023-506296-97-00 - Phase 3Taking peopleA Long-Term Study of Zasocitinib in Children and Teenagers With Plaque Psoriasis
- Where
- Catania, Padova, Rome
- Age
- 4 years to 17 years
- People
- 110 worldwide
- Run by
- Takeda
See details and how to joinNCT07250802 · EU 2025-522567-15-00 - Phase 3Taking peopleA Study to Assess Adverse Events, Change in Disease Activity, and How the Drug Moves Through the Body in Children With Juvenile Psoriatic Arthritis (jPsA) Receiving Subcutaneously Injected Risankizumab or Adalimumab
- Where
- Florence, Milan, Rome
- Age
- 5 years to 17 years
- People
- 40 worldwide
- Run by
- AbbVie
See details and how to joinNCT06100744 · EU 2023-506026-36-00 - No phaseTaking peopleClinical Study on the Medical Devices PROXERA PSOMED 20 and PROXERA PSOMED 40 for the Treatment of Plaque Psoriasis and Non-pustular Palmoplantar Psoriasis
- Where
- Chieti
- Age
- 18 years to 65 years
- People
- 35
- Run by
- ICIM International S.r.l.
See details and how to joinNCT07545902 - No phaseTaking peopleClinical Study on the Medical Device PROXERA PSOMED 30 for the Treatment of Nail Psoriasis: Evaluation of Safety and Efficacy
- Where
- Chieti
- Age
- 18 years to 65 years
- People
- 21
- Run by
- ICIM International S.r.l.
See details and how to joinNCT07546032 - Phase 3Taking peopleA Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis
- Where
- Cagliari, Ferrara, Milan, Naples, Novara
- Age
- 18 years and over
- People
- 320 worldwide
- Run by
- Janssen - Cilag International
See details and how to join2023-505121-14-00 - Phase 3Taking peopleStudy to Assess Efficacy, Safety and Tolerability of a Nail Patch in Patients With Nail Fragility, Mychosis, Psoriasis
- Where
- Milan
- Age
- 18 years and over
- People
- 72
- Run by
- Wooshin Labottach Co., Ltd.
See details and how to joinNCT07029516 - No phaseTaking peopleDietary Approach to Mild-to-moderate Psoriasis
- Where
- Palermo
- Age
- 18 years to 65 years
- People
- 82
- Run by
- University of Palermo
See details and how to joinNCT05644782 - Phase 4Taking peoplePotential Role of Guselkumab in Modulating PAIN Perception and Related Gene Pathways: a Proof-of-concept Study.
- Where
- Rome
- Age
- 18 years to 80 years
- People
- 26
- Run by
- Fondazione Policlinico Universitario Campus Bio-Medico
See details and how to joinNCT06974474